3

Ø

1-	3	ව	
----	---	---	--

(03-01) 51-0032	

Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

persons are required to respond to a collection of information unless it displays a valid OMB control number			
Attorney Docket No.		8375D	
First Inventor		Charles Raymond Degenhard	t
Assignee	The	Procter & Gamble Co.	
Substituted Heterocyclic Compounds For treating Multidrug Resistance			
Express Mail Label No.		ET992941996US	673

APPL	.ICA	TION	ELEMENTS
------	------	------	-----------------

See MPEP Chapter 600 concerning utility patent application contents.

Box Patent Application ADDRESS TO: U.S. Patent and Trademark Office P. O. Box 2327 Arlington, VA 22202

- 1. [X] Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)
- 2. [] Applicant claims small entity status (see 37 CFR §1.27)
- 3. [X] Specification Total Pages [79] (preferred arrangement set forth below)
 - Descriptive Title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

Drawing(s) (35 USC §113) Total Sheets []

Oath or Declaration

2.0

10 11

Total pages [2]

- Newly executed (original or copy) [X] Copy from a prior application (37 CFR §1.63(d)) (for continuation/divisional with Box 18 complete
 - DELETION OF INVENTORS Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§1.63(d)(2) and 1,33(b).
- 6. [] Application Data Sheet. See 37 CFR §1.76

7.	[] CD-ROM or CD-R in duplicate, large	table
	Computer Program (Appendix)	-
0	Alcohortide and/or Amine Asid Companso Co	.h

- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. [Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. [] CD-ROM or CD-R (2 copies); or
 - ii. ∏ Paper
 - c. [] Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS
9. [] Assignment Papers (cover sheet & document(s))
10. [] 37 CFR 3.73(b) Statement [] Power of Attorney (when there is an assignee)
11. [] English Translation Document (if applicable)
12. [] Information Disclosure [] Copies of IDS
Statement (IDS)/PTO-1449 Citations
13. [] Preliminary Amendment
 [X] Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. [] Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. [] Nonpublication Request under 35 U.S.C.
122(b)(2)(B)(i). Applicant must attach form
PTO/SB/35 or its equivalent.
17. [] Other:

18. If a CONTINUIN	IG APPLICATIO	N, check appropriate box and supply the re	equisite information below and in a preliminary
amendment, or in an App	lication Data Sheet ι	Inder 37 CFR §1.76:	
Continuation	[X] Divisional	Continuation-in-part (CIP)	of prior application No. 09/740,643

Prior application information: Examiner: R. Desai Group/Art Unit: <u>1625</u> For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

[X]	Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here
		27759 A. 1966 1 27759 A. 4 A. ST. ST. ST. ST. ST.

Name (Print/Type)	Kelly L. McDow-Dunham	Registration No. (Attorney/Agent)	43,787	
Signature	Celly 2. Ochon D	Date	November 29, 2001	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary despiting upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Patent Application, U.S. Patent and Trademark Office, P. O. Box 2327, Arington, VA 22202

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

	, .pp. 0.1		11100g1. 1010112002. Olling 0001 0002
	Patent and Trademark	ce:	U.S. DEPARTMENT OF COMMERCE
ас	collection of information unle	ess.	it displays a valid OMB control number

FEE	TR	AN	SMI	TT	AL
	for	FY	200	2	

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 740.00

Complete if Known			
Application Number			
Confirmation Number			
Filing Date	November 29, 2001		
First Named Inventor	Charles Raymond Degenhardt		
Examiner Name			
Group/Art Unit			
Attomey Docket No.	8375D		

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued) 3. ADDITIONAL FEES			
The Commissioner is hereby authorized to charge indicated				
fees and credit any over payments to:	Code (\$) Fee Description Fe	ee Paic		
Deposit Account Number 16-2480	105 130 Surcharge-late filing fee or oath	0		
Deposit Account Name The Procter & Gamble Company	127 50 Surcharge-late provisional filing fee or cover sheet			
Charge Any Additional Fee Required Under status. 37 C.F.R. §§1.16		0		
and 1.17	1	0		
end of the second of the secon	112 920* Requesting publication of SIR prior to Examiner's action	0		
FEE CALCULATION	113 1,840* Requesting publication of SIR after Examiner's action	0		
15 BASIC FILING FEE – Large Entity		0		
TANDAGIO FILING FEE – Laige Littiy		Ö		
Code (\$) <u>Fee Description</u> <u>Fee Paid</u>	· ·	0		
1€1 740 Utility filing fee [X]		0		
196 330 Design filing fee [128 1,960 Extension for reply within 5 th month	0		
108. 740 Reissue filing fee [119 320 Notice of Appeal	0		
144 160 Provisional filing fee [120 320 Filing a brief in support of an appeal			
### ### ###	•	0		
SUBTOTAL (1) (\$)[740]	138 1,510 Petition to institute a public use proceeding	0		
\$e ²	140 110 Petition to revive - unavoidable	0		
2. EXTRA CLAIM FEES – Large Entity		0		
		0		
Extra Fee from Fee	-			
<u>Claims</u> <u>Below</u> <u>Paid</u>		0		
Total Claims [16] - 20** = [0] x [0] = [0]		0		
Independent Claims [1] - 3** = [0] x [0] = [0]		0		
Multiple Dependent [0] = [0]	146 740 Filing a submission after final rejection	_		
** or number previously paid, if greater; For Reissues, see below		0		
Code (t) For Depositation	149 740 For each additional invention to be	п		
Code (\$) Fee Description	`	0		
103 18 Claims in excess of 20 102 84 Independent claims in excess of 3		0.0		
102 04 machenialit dalins in excess of 3	of a design application	u		
104 280 Multiple dependent claim, if not paid	* '''	0		
109 84 **Reissue independent claims over onginal patent	priority under 35 U.S.C. 119, 120, 121, or 365 (a) or ((c)		
110 18 **Reissue claims in excess of 20 & over original patent				
	Other fee (specify)	0		
	Other fee (specify)	C		
SUBTOTAL (2) (\$)[0]	* Reduced by Basic Filing Fee Paid SUBTOTAL(3) (\$) [0	01		

SUBMITTED BY			Complete (if applicable)		
Name (Print/Type)	Kelly L. McDow-Dunham	Registration No. (Attorney/Agent)	43,787	Telephone	(513) 634-0102
Signature	Kelly 2. DI	Bond	ì	Date	November 29, 2001

WARNING: Information on this form may become public. Credit Card Information should not be included on this form. Provide credit card Information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.